Compare Las Vegas Sands Corp. (LVS) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs Regeneron Pharmaceuticals Inc — how do they compare? Las Vegas Sands Corp. trades at $45.83 (market cap $29.44B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.8× Las Vegas Sands Corp.'s market cap, and Las Vegas Sands Corp. pays the higher dividend (2.64%). Which is the better fit depends on your goals.
| LVS | REGN | |
|---|---|---|
Market Cap | $29.44B | $83.19B |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $812.27 |
52-Week Low | $44.78 | $555.51 |
Enterprise Value | $41.33B | $77.90B |
Dividend Yield | 2.64% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $45.77, down 0.74% on the day, with a bearish technical signal and recent Q2 2026 earnings miss. The company shows strong fundamentals with revenue growth to $13.02B in 2025, a net income margin of 12.59%, and robust cash flow from operations of $3.02B. Analyst consensus remains bullish with a $60.75 price target and 59% buy ratings, supported by positive corporate news on ESG achievements and community initiatives.
The outlook for LVS is mixed; strong profitability and analyst optimism contrast with technical bearishness and high debt levels. Upside potential exists if earnings rebound, but risks include competitive pressures and macroeconomic sensitivity. The stock's current valuation at a P/E of 17.74 offers a reasonable entry if operational execution improves.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
